[Fulminant hepatitis].
Yasuda
Hiroshi
H
Division of Gastroenterology, Showa University Fujigaoka Hospital.
Yoshiba
Shinsyou
S
D000082:Acetaminophen / Q000009:adverse effects; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007052:Ibuprofen / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008775:Methylprednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D013997:Time Factors
D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D000082:Acetaminophen; D007052:Ibuprofen; D008775:Methylprednisolone